Vikram Purohit
Stock Analyst at Morgan Stanley
(1.80)
# 3,311
Out of 5,149 analysts
163
Total ratings
32.31%
Success rate
-7.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Maintains: Overweight | $11 → $18 | $6.95 | +158.99% | 3 | Feb 18, 2026 | |
| INCY Incyte | Maintains: Equal-Weight | $92 → $94 | $98.07 | -4.15% | 26 | Jan 6, 2026 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $31 → $34 | $25.18 | +35.03% | 3 | Oct 28, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $80 → $79 | $69.40 | +13.83% | 11 | Oct 20, 2025 | |
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $2.57 | +129.18% | 3 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $3.54 | +41.24% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $239.22 | +4.51% | 19 | May 5, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $164.05 | +15.82% | 19 | Feb 27, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $5.52 | +63.04% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $27.66 | +12.08% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $16 | $111.10 | -85.60% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $23.60 | -57.63% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $14.00 | -57.14% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $8.69 | +383.31% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $86.35 | -52.52% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $8.30 | +381.93% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $2.21 | +488.24% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $12.50 | +204.00% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $7.24 | +176.24% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $13.96 | -28.37% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.04 | +2,025.60% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $21.87 | -8.55% | 2 | Aug 5, 2020 |
COMPASS Pathways
Feb 18, 2026
Maintains: Overweight
Price Target: $11 → $18
Current: $6.95
Upside: +158.99%
Incyte
Jan 6, 2026
Maintains: Equal-Weight
Price Target: $92 → $94
Current: $98.07
Upside: -4.15%
Zenas BioPharma
Oct 28, 2025
Maintains: Overweight
Price Target: $31 → $34
Current: $25.18
Upside: +35.03%
Halozyme Therapeutics
Oct 20, 2025
Maintains: Overweight
Price Target: $80 → $79
Current: $69.40
Upside: +13.83%
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $2.57
Upside: +129.18%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $3.54
Upside: +41.24%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $239.22
Upside: +4.51%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $164.05
Upside: +15.82%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $5.52
Upside: +63.04%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $27.66
Upside: +12.08%
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $111.10
Upside: -85.60%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $23.60
Upside: -57.63%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $14.00
Upside: -57.14%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $8.69
Upside: +383.31%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $86.35
Upside: -52.52%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $8.30
Upside: +381.93%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $2.21
Upside: +488.24%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $12.50
Upside: +204.00%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $7.24
Upside: +176.24%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $13.96
Upside: -28.37%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.04
Upside: +2,025.60%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $21.87
Upside: -8.55%